Matches in Wikidata for { <http://www.wikidata.org/entity/Q94395950> ?p ?o ?g. }
Showing items 1 to 42 of
42
with 100 items per page.
- Q94395950 description "article by E Elias et al published 15 March 2019 in Journal of the Canadian Association of Gastroenterology" @default.
- Q94395950 description "article scientifique publié en 2019" @default.
- Q94395950 description "wetenschappelijk artikel" @default.
- Q94395950 description "наукова стаття" @default.
- Q94395950 name "A40 IBD PATIENTS RECEIVING INFLIXIMAB IN COMBINATION WITH AN IMMUNOMODULATOR ARE LESS LIKELY TO DEVELOP SECONDARY LOSS OF RESPONSE" @default.
- Q94395950 name "A40 IBD PATIENTS RECEIVING INFLIXIMAB IN COMBINATION WITH AN IMMUNOMODULATOR ARE LESS LIKELY TO DEVELOP SECONDARY LOSS OF RESPONSE" @default.
- Q94395950 type Item @default.
- Q94395950 label "A40 IBD PATIENTS RECEIVING INFLIXIMAB IN COMBINATION WITH AN IMMUNOMODULATOR ARE LESS LIKELY TO DEVELOP SECONDARY LOSS OF RESPONSE" @default.
- Q94395950 label "A40 IBD PATIENTS RECEIVING INFLIXIMAB IN COMBINATION WITH AN IMMUNOMODULATOR ARE LESS LIKELY TO DEVELOP SECONDARY LOSS OF RESPONSE" @default.
- Q94395950 prefLabel "A40 IBD PATIENTS RECEIVING INFLIXIMAB IN COMBINATION WITH AN IMMUNOMODULATOR ARE LESS LIKELY TO DEVELOP SECONDARY LOSS OF RESPONSE" @default.
- Q94395950 prefLabel "A40 IBD PATIENTS RECEIVING INFLIXIMAB IN COMBINATION WITH AN IMMUNOMODULATOR ARE LESS LIKELY TO DEVELOP SECONDARY LOSS OF RESPONSE" @default.
- Q94395950 P1433 Q94395950-60BD566A-5BAE-4217-ACDE-917C35EF028A @default.
- Q94395950 P1476 Q94395950-3C821862-86FB-45D9-9B1F-3B5547CE9DFF @default.
- Q94395950 P2093 Q94395950-0A567992-6403-48A9-83FA-AB9CEAC467DC @default.
- Q94395950 P2093 Q94395950-5C9AEF5C-A13A-4457-9B97-99C1FBAA496A @default.
- Q94395950 P2093 Q94395950-A5603F34-E890-4C6A-B762-EB4AFCF5FD89 @default.
- Q94395950 P2093 Q94395950-BC047A3B-684D-4E04-BE9A-32BD970F65DB @default.
- Q94395950 P2093 Q94395950-E16ED3AC-92F2-417B-8296-1D35D63AA62D @default.
- Q94395950 P2093 Q94395950-F0E052FA-420F-4F9D-BDE7-702E9A2F8209 @default.
- Q94395950 P304 Q94395950-99B4CE8D-5AD5-44F2-AE74-F664E6F089B4 @default.
- Q94395950 P31 Q94395950-050732C6-DC33-45BD-AC08-3076BDD17FD0 @default.
- Q94395950 P356 Q94395950-DD365CEB-82D6-422D-A34A-9F7F047C264C @default.
- Q94395950 P433 Q94395950-73BDD81A-C107-4A80-BF37-E11625E68948 @default.
- Q94395950 P478 Q94395950-64708CD0-E113-472E-9387-0E5FF4B79F50 @default.
- Q94395950 P577 Q94395950-6EC65D1F-EDC9-405E-BCF5-79F894AAB8C9 @default.
- Q94395950 P932 Q94395950-80568836-5659-443A-9B70-A6DFCC5CEC79 @default.
- Q94395950 P356 GWZ006.039 @default.
- Q94395950 P1433 Q68835690 @default.
- Q94395950 P1476 "A40 IBD PATIENTS RECEIVING INFLIXIMAB IN COMBINATION WITH AN IMMUNOMODULATOR ARE LESS LIKELY TO DEVELOP SECONDARY LOSS OF RESPONSE" @default.
- Q94395950 P2093 "A Oketola" @default.
- Q94395950 P2093 "C N Bernstein" @default.
- Q94395950 P2093 "E Elias" @default.
- Q94395950 P2093 "H Singh" @default.
- Q94395950 P2093 "L Targownik" @default.
- Q94395950 P2093 "S Krishnan" @default.
- Q94395950 P304 "80-81" @default.
- Q94395950 P31 Q13442814 @default.
- Q94395950 P356 "10.1093/JCAG/GWZ006.039" @default.
- Q94395950 P433 "Suppl 2" @default.
- Q94395950 P478 "2" @default.
- Q94395950 P577 "2019-03-15T00:00:00Z" @default.
- Q94395950 P932 "6512547" @default.